Tests DS-3939a alone or with other drugs in adults with solid tumors
Tests DS-3939a, alone or with other cancer drugs, in adults with solid tumors.
Plain-language title generated from the registry record
Registry title: A Study of DS-3939a in Participants With Solid Tumors
Key facts
- Where
- Ankara, TunisiaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced non-small cell lung cancer (a solid tumor) that cannot be removed by surgery or has spread. It tests DS-3939a alone or with other cancer drugs.
- Age
- 18 years or older (follow local rules if the legal age of consent is higher).
- Sex
- All sexes can join.
- Disease stage
- Stage IIIB or IIIC disease that cannot be treated with surgery or chemoradiation, or Stage IV non-squamous non-small cell lung cancer. The disease must be measurable by RECIST v1.1.
- Earlier treatment
- Substudy 1: no earlier systemic treatment for advanced or metastatic lung cancer. Substudy 2: earlier platinum-based chemotherapy, plus targeted therapy if there is a gene change (not EGFR), or anti-PD-1/PD-L1 antibody if there is none. Part 2 only: only 1 or 2 earlier lines of treatment for advanced disease.
- Biomarker or test result
- Substudy 2 depends on whether there is a gene change (AGA, not EGFR mutation). Heart pumping function (LVEF) must be 50% or more.
Main reasons for not taking part
- Earlier treatment targeting MUC1 or TA-MUC1, or with a topoisomerase 1 inhibitor or antibody-drug conjugate
- Spinal cord compression or active brain or central nervous system metastases
- Any history of interstitial lung disease or pneumonitis
- Active or uncontrolled HIV, hepatitis B or hepatitis C infection
- Stroke, mini-stroke or other arterial blood clot event in the past 6 months
Read by machine on 11 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes your lung cancer?
- Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
- Has your cancer spread to the brain?
Source: NCT07739966, who can take part
Where in Tunisia
- Ankara Bilkent Sehir Hastanesi (Ankara City Hospital)Ankara, TunisiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Daiichi Sankyo
- Trial code
- NCT07739966EU 2026-525218-75-00
- Record updated
- 10 November 2026
- Original description
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.Read full original descriptionShow less
A Phase 1b/2, Multicenter, 2-part, Open-label Trial to Evaluate DS-3939a in Participants With Solid Tumors
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.
Inclusion: Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures; Adults greater than or equal to (≥)18 years of age at the time the Main Trial ICF is signed (follow local regulatory requirements if the legal age of consent for trial participation is >18 years old); Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC; Has a left ventricular ejection fraction (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days of the first trial intervention; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 assessed no more than 14 days prior to initiation of trial interventions; Has adequate organ function; Participants must have measurable disease by investigator assessment according to RECIST v1.1; Additional Inclusion Criteria for Substudy 1:; Participants must not have received prior systemic therapy for locally advanced unresectable or metastatic NSCLC; Additional Inclusion Criteria for Substudy 2:; Participants with AGA (excluding EGFR mutation): Participants have been previously treated with targeted therapy for the AGA and platinum-based chemotherapy for the advanced disease setting; Participants without AGA: Participants have been previously treated with platinum-based chemotherapy and anti-programmed death-1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) antibody; Part 2 only: Participants must have received only 1 or 2 prior lines of anticancer therapy for the advanced disease setting.
Exclusion: Prior systemic anticancer therapy targeting MUC1 or TA-MUC1; Prior systemic anticancer therapy with topoisomerase 1 inhibitor or topoisomerase 1 inhibitor-based antibody-drug conjugate (ADCs) (e.g., datopotamab deruxtexan and Sacituzumab govitecan); Has multiple primary malignancies; Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening; Has active or uncontrolled human immunodeficiency virus (HIV) infection; Has active or uncontrolled hepatitis B virus (HBV)/hepatitis C virus (HCV) infection; Has spinal cord compression or clinically active central nervous system (CNS) metastases; Any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event; Current participation in other therapeutic investigational procedures, except for participation in long term survival follow-up (LTSFU) without any investigational treatment.